Patient Interest Seminar 21 st May Dr. Andrew Power Vice Chair New Drugs Sub group.

Slides:



Advertisements
Similar presentations
Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
Advertisements

What is commissioning? Paul McManus Pharmacist Advisor Yorkshire and the Humber Office North of England Specialised Commissioning Group North of England.
Medication Management
5th Annual PBM Pharmacy Informatics Conference
Changes to the NHS April 2013 How they affect services commissioned from pharmacies.
Directive EEC - PILs PATIENT ACCESS SCHEMES Christine Gilmour co-chair of NHS Scotland Patient Access Scheme Assessment Group.
MEDICINES SELECTION & FORMULARY MANAGEMENT
Pharmaceutical Sciences NON MEDICAL PRESCRIBING Non Medical Prescribing Alison Hogg.
“Rational Pharmacology” and Health Economics By Alan Maynard.
SMC Evaluation Programme. Overview Context Evaluation Programme –Stakeholders –SMC advice Conclusions.
Managing Medicines Use by PBC Groups in West Hertfordshire Dr Alison Davies.
Collaboration Across the Spectrum of Formularies in Saskatchewan: The RQHR Perspective Wm. Semchuk, MSc,PharmD,FCSHP Manager, Pharmacy Practice Regina.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
PAHO/WHO Seminar Brasilia October 2002 PAHO/WHO INTERNATIONAL SEMINAR ON CHALLENGES FOR COMPREHENSIVE PHARMACEUTICAL SERVICES BRASILIA, OCTOBER 2002 Experience.
1 “Medicines use review conducted in community pharmacy" Professor Ian Chi Kei Wong Department of Health Public Health Career Scientist The School of Pharmacy.
Promoting Excellence in Family Medicine Enabling Patients to Access Electronic Health Records Guidance for Health Professionals.
Student Fitness to Practise
NHS Formularies Fiona Graham Formulary Pharmacist NHS Lanarkshire.
NHS Lanarkshire Joint Formulary Fiona Graham Formulary Pharmacist.
VICTORIA MACKINNON Prescribing Adviser NHS Lanarkshire.
Clinical Pharmacy Basma Y. Kentab MSc..
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Chairman, Pharmaceutical Market Support Group
You need to consider whether a Patient Group Direction (PGD) would be appropriate for an area of practice that involves the supply or administration of.
Introduction To Pharmacy Practice
Development of Clinical Practice Guidelines for the NHS Dr Jacqueline Dutchak, Director National Collaborating Centre for Acute Care 16 January 2004.
1. How can we promote pharmacies and the full service available? Think about: How the NHS works with Local Authorities to enhance the role of community.
 Minor Ailment Service.  Policy To establish community pharmacies as the first port of call for the NHS treatment of common clinical.
NICE Decision Making Dr Katherine Payne North West Genetics Knowledge Park The University of Manchester
The Pharmaceutical Care of Patients with Long Term Conditions Deirdre Watt Team Leader, Community Pharmacy Scottish Government.
NHS Formularies Fiona Graham Formulary/Clinical Effectiveness Pharmacist NHS Lanarkshire.
IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE
SMC Horizon Scanning Anne Lee, Scottish Medicines Consortium Julia Earnshaw, GlaxoSmithKline.
Healthcare rationing is used by health insurers, the government and individuals to save money. Most of us believe that if there is a treatment available,
Liverpool Community Alcohol Services 0151 – 259 –
Assessment of Patient Knowledge Regarding Drugs Prescribed and Dispensed in Some Health Insurance Outpatient Clinics in Alexandria.
Independent Prescriber- Sunnymeed Practice Community Pharmacist- Boots The Chemist Ltd Clinical Pharmacist for North West Surrey CCG.
ACCESS TO MEDICINES - POLICY AND ISSUES
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
Scottish Medicines Consortium SMC RESPONSE TO EVALUATION Angela Timoney Vice Chair SMC 23 rd September 2008.
ABSTRACT Title: Developing National Formularies Based on the WHO Model Formulary Authors: Tisocki K 3, Laing RL 1, Hogerzeil H 1, Mehta DK 2, Ryan RSM.
Scottish Medicines Consortium - Approach to Cancer Medicines Dr Ken Paterson BOPA Symposium 13 September 2007.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
New Zealand Pharmacy Services Andi Shirtcliffe B. Pharm, PG Dip (Clin) Pharm, Reg Pharm NZ Chief Advisor – Pharmacy, New Zealand Ministry of Health.
Current Challenges and Future Developments in HTA in the UK Frances Macdonald, 23 rd September 2008 (A personal, Industry View)
Healthcare Improvement Scotland is supporting clinical engagement with NHS board Area Drug and Therapeutics Committees (ADTCs) to develop collaborative.
Medication Error Reduction Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
SMC Evaluation Project The View From Industry Martin Coombes Government Affairs Manager, AstraZeneca ABPI Representative SMC Evaluation Reference Group.
DIFFICULT DECISIONS IN HEALTH CARE Presentation to OJHOSC Dr Ljuba Stirzaker Oxfordshire Primary Care Trust 13 March 2008 ITEM JHO8(a) JHO3.MAR1308R03.ppt.
MEDICATION MANAGEMENT P&T COMMITTEE AND FORMULARY MANAGEMENT EMTENAN ALHARBI, Msc CLINICAL PHARMACIST.
SMC and the role of Public Involvement Action Duchenne Scottish Mini Conference 4 December 2015 Lindsay Lockhart Public Involvement Officer.
NATIONAL INITIATIVES: BEST PRACTICE AND LESSONS LEARNED FROM SCOTTISH EXPERIENCE Alan MacDonald Vice Chairman Scottish Medicines Consortium Hard Choices.
New medicines, new challenges: the SMC approach
Opportunities in 2012 and Beyond The Way Forward Stuart Semple Director of Pharmacy and Medicines Management Barts Health NHS Trust.
Putting Patients at the Centre of Care What can my Community Pharmacist do for me? Dr Tarlochan Gill Chairman, Kent & Medway Pharmacy Local Professional.
Presentation Developed for the Academy of Managed Care Pharmacy
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Private and confidential Community Pharmacy Future Four-or-more medicines support service Update on progress and next steps Approved18 th June 2012 This.
Pharmacy White Paper Building on Strengths Delivering the Future Overview.
Introduction Method Acknowledgements The impact of respiratory virtual clinics in primary care on responsible respiratory prescribing and inhaled corticosteroid.
Clinical Knowledge Summaries Overview
How are new treatments appraised
Health Technology Assessment
Principal recommendations
Victoria Gemmell1 Professor Alex Mullen2
Evaluating COPD Services
Issues on Dispensing Dr Percy Mahlathi.
Welcome. Supporting Realistic Medicine through the delivery of a Single National Formulary.
COMPUS Overview Denis Bélanger Heather Bennett Steve Graham
Community pharmacy and Primary Care Networks – what you need to know This presentation provides a brief summary on Primary Care Networks (PCNs) and the.
Presentation transcript:

Patient Interest Seminar 21 st May Dr. Andrew Power Vice Chair New Drugs Sub group

Objectives  SMC processes NDC & SMC NDC & SMC  Health Board Formulary processes  QALY tables

Scottish Medicines Consortium

SMC – multidisciplinary (30)  Physicians, pharmacists, health economists  NHS executives/finance managers  Pharmaceutical industry nominees (ABPI)  Public partners (3)  PR, Scottish Government representatives NDC - clinical/scientific (15)  Physicians, pharmacists, nurse, health economists, academics, industry nominees  Including Pharmacy Assessment Team and Health Economics Team Composition

Safety, quality and efficacy…

SMC Remit  National consortium of representatives of local drug and therapeutic committees  Provide advice to NHS Boards on: New medicines New medicines New formulations of older medicines New formulations of older medicines Major new indications Major new indications  Assess the need and clinical effectiveness including comparative efficacy  Assess the comparative cost-effectiveness  DO NOT assess safety

Assessment process

Scottish Medicines Consortium  Produce a Detailed Advice Document (DAD)  SMC may: Accept medicine for use in NHS Scotland Accept medicine for use in NHS Scotland Accepted for use in NHS Scotland (with restrictions) Accepted for use in NHS Scotland (with restrictions) Not recommend for use in NHS Scotland Not recommend for use in NHS Scotland  All advice can be found on the SMC website: uk uk uk

Count and annual share of SMC decisions, (excluding abbreviated and non-submissions)

QALYs  They are based on the number of years of life that would be added by the intervention. Each year in perfect health is assigned the value of 1.0 down to a value of 0 for death.  If the extra years would not be lived in full health, for example if the patient would lose a limb, or be blind or be confined to a wheelchair, then the extra life-years are given a value between 0 and 1 to account for this.

Cost-Effectiveness vs. Effectiveness  DRUG B  96% Cure Rate  £10 / patient  DRUG A  90% Cure Rate  £1 / patient With thanks to Dr. Andrew Walker, University of Glasgow

Cost-Effectiveness vs. Effectiveness  DRUG B  96% Cure Rate  £10 / patient  96 cures / £1000  DRUG A  90% Cure Rate  £1 / patient  900 cures / £1000

£270Stop smoking advice £40k to £600kMS treatment £12600CABG £5000Heart transplant £750Hip replacement Cost per QALYIntervention

Post SMC: local formulary process New medicine / indication / formulation released onto market SMC review medicine SMC accept for use in NHS ScotlandSMC do not accept for use in NHS Scotland Medicine cannot be considered for addition to the GGC Formulary Manufacturer can make a re-submission to SMC Formulary and New Drugs Sub-committee (FND) consider medicine and make recommendation Accepted for addition to Formulary (restrictions may apply) Rejected for addition to the Formulary Area Drug and Therapeutic Committee review FND recommendation Formulary Appeals Process

What is a formulary?  Generally, a list of medicine which the vast majority of prescribing should come from May be a simple list May be a simple list May include additional information and guidance May include additional information and guidance  Can be applicable from anything from a single practice, to health board to country (e.g. BNF)  Formulary Management is the term given all processes linked to the Formulary including production, review and measurement of adherence

Why produce a Formulary?  Promote cost- effective drug use  Maximise given resources Limited resources Limited resources Increasing pressures Increasing pressures  Minimise risk  Maximise procurement

Fact or Fiction?   Medicines not accepted by SMC can not be prescribed by GPs Fiction – GP in general should follow SMC advice, but in exceptional cases may prescribe ‘non-SMC’ medicines   In most health boards, GPs are able to appeal to have a medicine reconsidered for inclusion in the local formulary Fact – most health boards have an appeal process that GPs can access   GPs are independent contractors and do not have to stick to any agreed local formulary Fact with some fiction – GPs are independent contractors and can prescribe non-formulary medicines where they see fit, though they are requested to follow local formularies. However, it should be noted that GPs are contracted to an NHS health board and widespread prescribing of medicines not accepted by SMC or non-Formulary without good reason could be deemed as inappropriate prescribing which may be considered a breach of contract.

ADTC  ADTC consider SMC advice for local implementation Consider local needs of the population Consider local needs of the population Opinions of relevant local clinicians and groups Opinions of relevant local clinicians and groups Consider what is on Formulary already Consider what is on Formulary already  Generally, approximately 85% of medicines accepted by SMC will be added to the Formulary

Formulary adherence (GGC)  The Preferred List is a subset of about 350 medicines covering conditions managed in Primary Care  Current average adherence for the year is 74%  Adherence to the full formulary is unknown, but estimated at >90%

Objectives  SMC processes NDC & SMC NDC & SMC  Health Board Formulary processes  QALY tables